Cyclacel Pharmaceuticals, Inc. (CYCC)
Market: NASD |
Currency: USD
Address: 200 Connell Drive
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Show more
📈 Cyclacel Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
<0%
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.062500 |
- |
2025-05-12 |
- |
Stock split |
| $0.150000 |
- |
2025-04-29 |
- |
Dividend payout |
|
Total Amount for 2025: $0.212500 |
| 2023 |
- |
$0.066667 |
- |
2023-12-18 |
- |
Stock split |
|
Total Amount for 2023: $0.066667 |
| 2020 |
- |
$0.050000 |
- |
2020-04-15 |
- |
Stock split |
|
Total Amount for 2020: $0.050000 |
| 2016 |
- |
$0.083333 |
- |
2016-05-31 |
- |
Stock split |
|
Total Amount for 2016: $0.083333 |
📅 Earnings & EPS History for Cyclacel Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2026-05-12 (estimated upcoming) | - |
| 2026-03-31 (estimated upcoming) | - |
| 2025-11-10 (estimated upcoming) | - |
| 2025-11-09 (estimated upcoming) | - |
| 2025-08-12 (estimated upcoming) | - |
| 2025-08-11 (estimated upcoming) | - |
| 2025-05-15 | - |
| 2025-05-14 | - |
| 2025-05-13 | - |
| 2025-05-12 | - |
| 2025-05-11 | - |
| 2025-04-02 | -0.33 |
| 2025-04-02 | - |
| 2025-03-16 | - |
| 2024-11-12 | -0.18 |
| 2024-08-14 | -0.72 |
| 2024-08-13 | -0.72 |
| 2024-05-14 | -2.27 |
| 2024-05-13 | -2.27 |
| 2024-03-19 | -6.23 |
| 2024-03-18 | -6.23 |
| 2023-11-13 | -0.49 |
| 2023-11-12 | -0.49 |
| 2023-08-09 | -0.44 |
| 2023-08-08 | -0.44 |
| 2023-05-11 | -0.47 |
| 2023-05-10 | -0.47 |
| 2023-03-06 | -0.6 |
| 2023-03-05 | -0.6 |
| 2022-11-09 | -0.42 |
| 2022-11-08 | -0.42 |
| 2022-08-10 | -0.46 |
| 2022-08-09 | -0.46 |
| 2022-05-11 | -0.42 |
| 2022-05-10 | -0.42 |
| 2022-03-28 | -0.54 |
| 2022-03-27 | -0.54 |
| 2021-11-10 | -0.54 |
| 2021-11-09 | -0.54 |
| 2021-08-11 | -0.56 |
| 2021-08-10 | -0.56 |
| 2021-05-12 | -0.5 |
| 2021-05-11 | -0.5 |
| 2021-02-25 | -1.34 |
| 2021-02-24 | -1.34 |
| 2020-11-11 | -0.47 |
| 2020-11-10 | -0.47 |
| 2020-08-12 | -0.58 |
| 2020-08-11 | -0.58 |
| 2020-05-12 | -1.48 |
| 2020-05-11 | -1.48 |
| 2020-02-26 | -2.8 |
| 2020-02-25 | -2.8 |
| 2019-11-13 | -2.2 |
| 2019-11-12 | -2.2 |
| 2019-08-12 | -2.2 |
| 2019-05-13 | -2.8 |
| 2019-03-26 | -3.4 |
| 2018-11-11 | -3.6 |
| 2018-08-08 | -3.2 |
| 2018-05-13 | -2.4 |
| 2018-03-27 | - |
| 2017-11-01 | - |
| 2017-08-08 | - |
| 2017-05-10 | - |
| 2017-03-27 | -13.8 |
| 2016-11-13 | -17.2 |
| 2016-08-09 | - |
| 2016-05-10 | - |
| 2016-03-23 | -24 |
| 2015-11-11 | -19.2 |
| 2015-08-10 | - |
| 2015-05-11 | -45.6 |
| 2015-03-23 | -50.4 |
| 2014-11-10 | -52.8 |
| 2014-08-11 | -52.8 |
| 2014-05-12 | -60 |
| 2014-03-24 | -45.6 |
| 2013-11-11 | -76.8 |
| 2013-08-13 | 24 |
| 2012-08-13 | -100.8 |
| 2012-05-13 | -100.8 |
| 2012-03-28 | -117.6 |
| 2011-11-13 | -117.6 |
| 2011-08-10 | -134.4 |
| 2011-05-11 | -168 |
| 2011-03-22 | -117.6 |
| 2010-11-10 | -184.8 |
| 2010-08-04 | -302.4 |
| 2010-05-12 | -302.4 |
| 2010-03-22 | -302.4 |
| 2009-11-02 | -218.4 |
| 2009-08-05 | -571.2 |
| 2009-05-13 | -420 |
| 2009-03-30 | -655.2 |
| 2008-11-05 | -1444.8 |
| 2008-08-06 | -705.6 |
| 2008-05-08 | -520.8 |
| 2008-03-10 | -940.8 |
| 2007-11-06 | -352.8 |
| 2007-08-08 | -302.4 |
| 2007-05-09 | -453.6 |
| 2007-03-14 | -604.8 |
| 2006-11-12 | -571.2 |
| 2006-08-13 | -806.4 |
| 2006-05-15 | -3040.8 |
| 2006-03-21 | -3024 |
| 2005-11-13 | -10752 |
| 2005-08-14 | -5040 |
| 2005-05-15 | -6216 |
| 2005-03-30 | -8400 |
| 2004-11-10 | -7728 |
| 2004-08-11 | -6888 |
| 2004-05-12 | -27048 |
📰 Related News & Research
No related articles found for "cyclacel pharmaceuticals".
